Session » (LB19–LB24) Late-Breaking Abstracts
- 8:00AM-8:15AM
-
Abstract Number: LB19
Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial
- 8:15AM-8:30AM
-
Abstract Number: LB20
Efficacy and Safety of Deucravacitinib up to Week 52: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs
- 8:30AM-8:45AM
-
Abstract Number: LB21
IDH1/2 Somatic Hotspot Mutations as Independent Drivers of Autoinflammation
- 8:45AM-9:00AM
-
Abstract Number: LB22
Early Evidence of Proof-of-Concept of an Albumin-DNASE1L3 Fusion Protein (NTR-441) for the Rapid Enzymatic Inactivation of NETs in SLE with DNASE1L3-Deficiency
- 9:00AM-9:15AM
-
Abstract Number: LB23
A Phase 1 Study of Autologous CAR-Treg Cells in Refractory Rheumatoid Arthritis: Interim Report of Safety and Efficacy